Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Contact information



Primary contact

Ms Liz-Anne Lewsley


Contact details

Beatson Oncology Centre
1053 Great Western Road
G12 0YN
United Kingdom
+44 141 301 7193

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

BriTROC1: Sample collection study to investigate the role of Homologous Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer



Study hypothesis

The prevalence of patients with pre-existing Homologous Recombination Deficiency (HRD), including germline and somatic BRCA1 and BRCA2 mutation and epigenetic silencing, will be higher in platinum-sensitive relapsed populations than in platinum-resistant patients. Taken together with mutation analysis of other HRD genes, the overall proportion of HRD in platinum-sensitive relapsed high grade serous ovarian cancer (HGSOC) may be 50-60%.

Examination of HRD biomarkers in biopsy tissue at the time of relapse, together with comparison with original tissue and germline DNA, will identify markers of platinum response as well as novel mechanisms of resistance.

Ethics approval

NRES Committee East of England - Cambridge Central, 23/08/2012, ref: 12/EE/0349

Study design

Multi-centre centre non-randomised sample collection observational study

Primary study design


Secondary study design

Cohort study

Trial setting


Trial type


Patient information sheet

Patient information sheet is available on the Cancer Research UK Clinical Trials Unit website:


Topic: National Cancer Research Network; Subtopic: Gynaecological Cancer; Disease: Ovary/Fallopian tube


Imaging guided (Ultrasound or CT), intra-operative or other suitable biopsies will be taken for research purposes from women who meet the eligibility criteria and who have been given written, informed consent. Blood will also be taken for storage of plasma and extraction of genomic DNA. Ascites will be collected if present and if drainage is deemed clinically indicated. For patients who consent, a further biopsy at subsequent relapse of disease will be taken. Patients will not be followed up within the context of this study.

Intervention type



Not Applicable

Drug names

Primary outcome measure

To obtain 300 fit-for purpose tumour biopsies from women with relapsed high grade serous ovarian cancer. Patients will have biopsy at baseline. This will take place at baseline after consent.

Secondary outcome measures

1. Assessment of mutations in HRD genes, BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, in relapsed HGSOC samples by targeted sequencing
2. Comparison of allelic ratio of BRCA1 and BRCA2 in relapsed HGSOC and archival tumour samples taken at the time of diagnosis
3. Analysis of mutations in TP53 (positive control for high grade serous pathology), PTEN, APC, BRAF, KRAS, PIK3CA in relapsed HGSOC and archival tumour samples
4. Assessment of germline DNA mutations in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 in women with relapsed HGSOC
5. Assessment of methylation of BRCA1 and BRCA2 in relapsed HGSOC and archival tumour samples taken at the time of diagnosis

Timepoints: Baseline blood samples and pre chemotherapy (cycles 1 and 2, optional), archival tumour samples from original surgery.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Patients with recurrent histologically-proven high grade serous ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer.
2. Patients may have received no more than two lines of prior chemotherapy
3. Availability of formalin-fixed, paraffin-embedded tissue taken at the time of original diagnosis of high grade serous ovarian cancer. This may be primary surgical debulking specimen OR core biopsy. For those with only a core biopsy from time of diagnosis, availability of specimen taken at interval debulking surgery is desirable, but not essential.
4. Patients must have disease deemed suitable for imaging-guided biopsy (ultrasound or CT) by an experienced radiologist.
5. Target Gender: Female, age ≥ 18 years
6. Written informed consent.
7. Able to apply with study procedures.
8. Life expectancy > 3 months
9. No contraindication to biopsy as appropriate

Participant type


Age group




Target number of participants

UK Sample Size: 300

Participant exclusion criteria

1. Ovarian, primary peritoneal or fallopian tube cancer of non-high grade serous pathology i.e. low grade serous, clear cell and endometrioid as well as carcinosarcoma/Malignant Mixed Mullerian Tumor (MMMT)
2. Borderline/low malignant potential tumours
3. Any non-epithelial ovarian malignancy
4. Patients with asymptomatic rising CA125 with no radiological evidence of recurrent ovarian cancer.
5. Original diagnosis of high grade serous cancer made on cytology only

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Beatson West of Scotland Cancer Centre
1053 Great Western Road
G12 0YN
United Kingdom

Sponsor information


NHS Greater Glasgow & Clyde (UK)

Sponsor details

Tennent Building
38 Church Street
G11 6NT
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Ovarian Cancer Action (UK)

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

Other non-profit organizations


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

19/02/2020: Cancer Research UK lay results summary link added to Results (plain English). 09/05/2017: The overall trial end date has been updated from 11/12/2015 to 30/08/2018 and the recruitment end date has been updated from 11/12/2015 to 30/08/2017.